文献速递糖尿病肥胖与代谢综合征

SGLT2抑制剂托格列净通过改善脂肪组织抗脂解效应减弱体重下降

Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

本研究整合两项为期52周的托格列净3期试验数据,分析774例2型糖尿病患者。结果显示体重下降在24至52周间趋于平台,空腹胰岛素持续降低而游离脂肪酸先升后降,脂肪组织胰岛素抵抗指数(Adipo-IR)持续下降,且基线Adipo-IR较高者52周体重下降更明显。

要点

  • 托格列净治疗52周体重下降在24周后趋于平台
  • Adipo-IR从基线至52周持续下降,抗脂解效应改善
  • 基线Adipo-IR较高者52周体重下降更明显

核心结论

  • 脂肪组织抗脂解效应改善可能减弱进行性脂解,从而 attenuate SGLT2i 诱导的后续体重下降。

研究设计与样本

  • 整合分析两项托格列净3期研究,为期52周,纳入774例2型糖尿病患者。
  • 以空腹胰岛素与空腹游离脂肪酸乘积计算的Adipo-IR评估抗脂解效应。

主要发现

  • 体重在24至52周间趋于平台,此前显著下降。
  • 空腹胰岛素从基线至24周显著下降并维持至52周。
  • 空腹游离脂肪酸显著升高,24周达峰后至52周下降。
  • Adipo-IR在52周内持续下降,24周和52周分别较基线变化-3.6和-6.2 mmol/L·pmol/L(P < 0.001)。
  • 基线Adipo-IR较高与52周体重下降更多独立相关。

关键数值与推荐

  • Adipo-IR变化:24周-3.6 mmol/L·pmol/L,52周-6.2 mmol/L·pmol/L,基线 vs 24周和52周及24周 vs 52周均P < 0.001。

临床怎么用

  • 长期使用SGLT2i时应关注脂肪组织胰岛素抵抗变化,其改善可能减弱后续减重效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Although calorie loss from increased urinary glucose excretion continues after long-term treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2is), the mechanisms of the attenuated weight loss due to SGLT2is are not well known. OBJECTIVE: To examine the mechanism of the attenuated weight loss during long-term treatment with an SGLT2i, tofogliflozin, focusing on the antilipolytic effect of insulin on adipose tissue. DESIGN AND PARTICIPANTS: An integrated analysis was performed using data from two phase 3 studies of 52 weeks of tofogliflozin administration. The antilipolytic effect was evaluated using adipose tissue insulin resistance (Adipo-IR) calculated from the product of the levels of fasting insulin (f-IRI) and fasting free fatty acids (f-FFAs). RESULTS: Data from 774 patients with type 2 diabetes (mean age, 58.5 years; glycosylated hemoglobin, 8.1%; body mass index, 25.6 kg/m2; estimated glomerular filtration rate, 83.9 mL/min/1.73m2; 66% men) were analyzed. Weight loss plateaued between weeks 24 and 52 after decreasing significantly. f-IRI levels decreased significantly from baseline to week 24, and the decrease was maintained until Week 52. f-FFA levels significantly increased, peaked at week 24, then declined from weeks 24 to 52. Adipo-IR levels declined progressively throughout the 52 weeks (-3.6 mmol/L·pmol/L and -6.2 mmol/L·pmol/L at weeks 24 and 52, respectively; P < 0.001 baseline vs weeks 24 and 52 and week 24 vs week 52). Higher baseline Adipo-IR levels were independently associated with greater weight loss at week 52. CONCLUSION: The improved antilipolytic effect in adipose tissue may attenuate progressive lipolysis, leading to attenuating future weight loss induced by an SGLT2i in patients with type 2 diabetes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Yoshida A, Matsubayashi Y, Nojima T, et al. Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin. J Clin Endocrinol Metab. 2019. PMID: 30811541. doi:10.1210/jc.2018-02254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。